Type 2 diabetes is diagnosed by exclusion in most clinics: an adult with a high glucose who is not obviously in ketoacidosis gets the type 2 label. That works most of the time and misses a real minority. Latent autoimmune diabetes in adults is autoimmune beta cell destruction that progresses slowly enough to look like type 2 for months or years.

What LADA is

LADA is defined by three features: onset in adulthood, usually age 30 or above, the presence of diabetes associated autoantibodies, and no need for insulin for at least six months after diagnosis. Glutamic acid decarboxylase 65 antibodies are the most commonly positive, present in approximately 90 percent of people with LADA. The Cleveland Clinic Journal of Medicine review in 2025 estimates that 4 to 14 percent of adults carrying a type 2 diagnosis may in fact have LADA.

Clues that should prompt antibody testing

The features that should raise the question are a normal or only slightly elevated BMI, a younger age at diagnosis, a personal or family history of autoimmune disease such as Hashimoto's thyroiditis or celiac disease, unintentional weight loss, and glucose that climbs faster than expected on oral medication. The 2026 ADA Standards of Care recommend standardized islet autoantibody testing to classify diabetes in adults whose features overlap with type 1 diabetes, including younger age at diagnosis, unintentional weight loss, ketoacidosis or a short time to insulin treatment.

Feature	Type 2 diabetes	LADA	Type 1 diabetes
Age at onset	Usually over 40	Usually 30 and over	Any age, often younger
Islet autoantibodies	Negative	Positive, GAD65 in about 90 percent	Positive in most
C-peptide	Normal or high	Falls over time	Low or undetectable
Time to insulin	Often years	At least six months, then progressive	Usually immediate

Why getting the label right matters

Classification changes treatment and safety. Someone with progressive autoimmune beta cell loss will eventually need insulin, and delaying it risks ketoacidosis, which is a medical emergency. It also changes what to expect from weight loss: remission strategies that work in type 2 diabetes do not restore beta cells that have been destroyed. C-peptide is the marker of remaining beta cell function and guides how urgently insulin is needed.

If you were labelled type 2 and you are lean, have another autoimmune condition, or your glucose is rising quickly despite good adherence, ask directly for GAD65 antibodies and a C-peptide drawn with a simultaneous glucose. Those two tests, done once, answer a question that otherwise gets deferred for years.

C-peptide is interpreted alongside a simultaneous glucose, since a low value during hypoglycemia means something different from a low value with hyperglycemia. The Cleveland Clinic Journal of Medicine review describes three practical bands of residual beta cell function: preserved above 0.7 nmol/L, partial 0.3 to 0.7 nmol/L, and significantly impaired below 0.3 nmol/L.

Autoantibodies used in classification are GAD65, IA-2, ZnT8 and insulin autoantibodies. GAD65 has the highest yield in adults. A single positive antibody in an adult with an otherwise typical type 2 phenotype should be interpreted with care, since low titre positivity occurs in the general population. The 2026 ADA Standards also recommend autoantibody screening for presymptomatic type 1 diabetes in people with a family history or known high genetic risk.

Could my type 2 diabetes actually be type 1 or LADA?

What LADA is

Clues that should prompt antibody testing

Why getting the label right matters

Sources

What LADA is

Clues that should prompt antibody testing

Why getting the label right matters

Sources

Related